Homearrow Blogsarrow Galleri® Multi-Cancer Early Detection Test: Comprehensive Overview
July 09, 2025

Galleri® Multi-Cancer Early Detection Test: Comprehensive Overview

The Galleri® test offers a groundbreaking approach to early cancer detection through a simple blood draw, identifying signals for multiple cancer types.

Galleri Test for Early Cancer Detection

Galleri® Multi-Cancer Early Detection Test: A Comprehensive Overview

Introduction

Early detection of cancer significantly increases the chances of successful treatment and survival. Traditional screening methods focus on specific cancers, leaving many types undetected until advanced stages. The Galleri® Multi-Cancer Early Detection (MCED) test by GRAIL introduces a novel approach, aiming to identify multiple cancer types through a single blood draw.

Understanding the Galleri® Test

What is the Galleri® Test?

The Galleri® test is a blood-based screening tool designed to detect signals associated with over 50 types of cancer. It analyzes cell-free DNA (cfDNA) in the bloodstream for abnormal methylation patterns indicative of cancer. This method allows for the identification of cancer signals even before symptoms manifest.

How Does It Work?

Cancers release cfDNA into the bloodstream, which carries specific methylation patterns. The Galleri® test employs next-generation sequencing and machine learning algorithms to detect these patterns, identifying the presence of cancer and predicting its tissue of origin. This information assists healthcare providers in guiding further diagnostic evaluations.

Cancers Detected by Galleri®

The Galleri® test can detect a wide range of cancers, including:

  • Pancreatic

  • Esophageal

  • Ovarian

  • Liver

  • Gallbladder

  • Head and Neck

  • Lymphoma

  • Multiple Myeloma

  • Prostate

  • Colorectal

  • Breast

  • Lung

These cancers often lack routine screening methods, making early detection challenging. The Galleri® test addresses this gap by providing a broader screening approach.

Performance Metrics

Sensitivity and Specificity

The Galleri® test has demonstrated high specificity, minimizing false-positive results. Sensitivity varies depending on cancer type and stage. For instance, sensitivity for detecting pancreatic cancer is approximately 83.7%, while for esophageal cancer, it's around 85.0%. These figures highlight the test's potential in identifying cancers that are typically diagnosed at later stages.

Cancer Signal Origin Prediction

Upon detecting a cancer signal, the Galleri® test predicts the tissue or organ of origin with high accuracy. This prediction aids clinicians in directing subsequent diagnostic procedures, streamlining the path to diagnosis.

Clinical Studies and Trials

PATHFINDER Study

The PATHFINDER study evaluated the clinical implementation of the Galleri® test in over 6,600 participants aged 50 and above. Results indicated that adding the Galleri® test to standard screenings approximately doubled the number of cancers detected. The median time to diagnostic resolution was 79 days, underscoring the test's efficiency in guiding further evaluations.

PATHFINDER 2 Study

Building on the initial study, PATHFINDER 2 involved over 25,000 participants. Preliminary results showed a substantial increase in cancer detection compared to the earlier study, reinforcing the test's utility in a broader population.

Limitations of the Galleri® Test

Not FDA-Approved

As of now, the Galleri® test has not received approval from the U.S. Food and Drug Administration (FDA). It is available as a Laboratory Developed Test (LDT) under the Clinical Laboratory Improvement Amendments (CLIA) regulations.

False Positives and Negatives

Like all screening tests, the Galleri® test can yield false-positive or false-negative results. A positive result indicates the presence of a cancer signal but does not confirm a cancer diagnosis. Further diagnostic evaluations are necessary to confirm the presence of cancer.

Not a Replacement for Routine Screenings

The Galleri® test is intended to complement, not replace, existing cancer screening methods. Routine screenings for cancers like breast, cervical, colorectal, and prostate remain essential.

Eligibility and Usage

The Galleri® test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older. It requires a prescription from a licensed healthcare provider and should be used in conjunction with routine cancer screenings.

Cost and Accessibility

The test is currently priced at $949 and is not covered by insurance. However, flexible payment options are available to increase accessibility.

Conclusion

The Galleri® Multi-Cancer Early Detection test represents a significant advancement in cancer screening, offering the potential to identify multiple cancer types through a single blood draw. While it is not a substitute for routine screenings and has limitations, its ability to detect cancers that lack standard screening methods positions it as a valuable tool in early cancer detection strategies.

As research continues and more data becomes available, the Galleri® test may play an increasingly prominent role in comprehensive cancer screening programs.

References

  1. GRAIL. (n.d.). Multi-cancer early detection. Retrieved from https://grail.com/multi-cancer-early-detection/

  2. GRAIL. (n.d.). Galleri Test Sensitivity & Specificity. Retrieved from https://www.galleri.com/hcp/galleri-test-performance

  3. GRAIL. (n.d.). Early Detection of Cancer with a Signal - Galleri® Test. Retrieved from https://www.galleri.com/hcp/the-galleri-test-2

  4. GRAIL. (n.d.). What is the Galleri Multi-Cancer Early Detection Test? Retrieved from https://www.galleri.com/what-is-galleri

  5. GRAIL. (n.d.). Frequently Asked Questions (FAQs) for Providers. Retrieved from https://www.galleri.com/hcp/faqs

  6. GRAIL. (n.d.). Discussing Multi-Cancer Early Detection With Your Patients. Retrieved from https://assets.galleri.com/statics/Downloads/Galleri-Discussion-Guide-for-HCPs_FINAL.pdf

  7. GRAIL. (n.d.). Galleri®, The GRAIL Multi-Cancer Early Detection Test. Retrieved from https://specialdocs.com/wp-content/uploads/2023/03/Galleri-Deep-Dive-for-Providers.pdf

  8. GRAIL. (n.d.). Final Results From PATHFINDER Study of GRAIL’s Multi-Cancer Early Detection Blood Test Published in The Lancet. Retrieved from https://grail.com/press-releases/final-results-from-pathfinder-study-of-grails-multi-cancer-early-detection-blood-test-published-in-the-lancet/

  9. GRAIL. (n.d.). GRAIL Announces Positive Top-Line Results From The Galleri® PATHFINDER 2 Registrational Study. Retrieved from https://grail.com/press-releases/grail-announces-positive-top-line-results-from-the-galleri%E2%93%A1-pathfinder-2-registrational-study/(grail.com, galleri.com, galleri.com, galleri.com, assets.galleri.com, specialdocs.com, grail.com, grail.com)

Note: This article is for informational purposes only and does not constitute medical advice. Always consult with a healthcare provider for medical guidance.